益盛药业(002566) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥157,716,894.39, representing a decrease of 13.21% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥2,528,970.69, down 77.10% year-over-year[2] - The net profit after deducting non-recurring gains and losses was -¥106,989.34, a decline of 101.43% compared to the previous year[2] - Total operating revenue for Q3 2024 was CNY 505.56 million, a decrease of 22.36% compared to CNY 651.15 million in the same period last year[14] - Net profit for Q3 2024 was CNY 33.40 million, a decline of 44.66% compared to CNY 60.20 million in Q3 2023[15] - Total comprehensive income for the period was CNY 33,402,435.53, compared to CNY 60,199,120.13 in the previous period, reflecting a decrease of approximately 44.6%[16] - Basic and diluted earnings per share were both CNY 0.1084, down from CNY 0.1767 in the previous period, indicating a decline of about 38.6%[16] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥41,175,388.85, down 74.64% year-over-year[2] - Cash inflow from operating activities totaled CNY 600,832,070.69, a decrease of 24.5% from CNY 796,571,102.42 in the previous period[17] - Net cash flow from operating activities was CNY 41,175,388.85, down 74.7% from CNY 162,346,702.32 in the previous period[17] - Cash outflow from investment activities was CNY 460,945,934.21, significantly higher than CNY 131,973,313.16 in the previous period[18] - Net cash flow from investment activities was -CNY 355,688,058.84, compared to -CNY 70,053,976.65 in the previous period, indicating a worsening investment position[18] - Cash inflow from financing activities was CNY 600,000,000.00, an increase from CNY 520,000,000.00 in the previous period[18] - Net cash flow from financing activities was -CNY 64,312,218.07, compared to a positive CNY 10,466,175.11 in the previous period, showing a shift to a net outflow[18] - The ending balance of cash and cash equivalents was CNY 108,908,752.89, down from CNY 446,022,778.54 in the previous period, reflecting a decrease of approximately 75.6%[18] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥3,004,867,731.15, a decrease of 1.37% from the end of the previous year[3] - The company's total assets as of Q3 2024 were CNY 3.00 billion, a decrease from CNY 3.05 billion at the end of the previous year[13] - Total liabilities decreased to CNY 688.69 million in Q3 2024 from CNY 714.30 million in the same period last year[13] - Shareholders' equity attributable to the parent company was ¥2,219,385,374.40, down 0.62% from the previous year-end[3] - The company's equity attributable to shareholders was CNY 2.22 billion, down from CNY 2.23 billion year-over-year[13] Investments and Financial Assets - The company reported a significant increase in trading financial assets, which rose by 320.70% to ¥433,245,468.90[7] - Investment income increased by 156.11% to ¥4,793,304.18, driven by higher returns from financial products[7] - The company reported an investment income of CNY 4.79 million for Q3 2024, compared to CNY 1.87 million in the previous year[15] - The company's trading financial assets increased significantly from 102,982,228.44 CNY to 433,245,468.90 CNY[10] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,678[8] - Zhang Yisheng holds 39.08% of shares, totaling 129,348,530 shares[8] Regulatory and Governance Issues - The company is addressing issues related to shareholding transparency and has a plan for reducing shareholding discrepancies[9] - Liu Jianming is in the process of reducing his held shares to ensure accurate information disclosure[10] - The company has received regulatory notifications regarding past shareholding issues and is implementing corrective measures[9] Operating Costs and Expenses - Total operating costs for Q3 2024 were CNY 487.97 million, down 18.69% from CNY 600.42 million year-over-year[14] - Research and development expenses for Q3 2024 amounted to CNY 14.38 million, slightly down from CNY 15.35 million in the previous year[14] - Financial expenses surged by 1945.90% to ¥4,351,479.19, primarily due to a decrease in interest income from agreement deposits[7] Future Outlook - The company plans to focus on market expansion and new product development in the upcoming quarters[12]